Psi, a global CRO out of Switzerland, has expanded into South Africa, touting the nation's diversity and regulatory environment as ideal for patient recruitment and drug development.
Pfizer has agreed to sell 260 million doses of its pneumococcal vaccine Prevnar 13 at a small fraction of their usual price.
Eighteen more GlaxoSmithKline employees are being detained in China as authorities dig deeper into the bribery investigation. And GSK's former China head Mark Reilly--replaced just last week--will soon be back in the country to help police with the probe.
Ascendancy Healthcare has tapped Quintiles to help it capitalize on China's booming pharmaceutical market, asking the world's largest CRO to help it choose, develop and market in-licensed therapies.
Against the backdrop of an ongoing government bribery probe in China, GlaxoSmithKline is shuffling its senior management there. Herve Gisserot is taking over.
For Zimmer, higher net sales in the U.S. and neighboring countries helped counter some declines in the Asia-Pacific region, leading to a 2012 second quarter with solid growth.
GlaxoSmithKline is looking for a partner that can help it crack the vaccine market in China. But vaccines can't return the same margins in these markets as they do in the West, and that is where manufacturing is expected to make a difference in closing the gap.
A San Francisco startup is plowing ahead developing a low-cost endoscopic device at a fraction of the price of products currently on the market. Such an advance could give Olympus and other competitors a run for their money, but the company's co-founder insists he'll pitch it in emerging markets.
GlaxoSmithKline CEO Andrew Witty faced a flurry of questions about China when he stood up to talk about second-quarter earnings--and he bowed out of the conference call before answering many of them. But he made a few proclamations that distanced the home office from the high-profile corruption scandal. In fact, he blamed the locals.
Despite the negative attention of the ongoing corruption probe, GlaxoSmithKline is still pressing ahead with its Chinese expansion plans, and its vaccine unit is a major part of the strategy.